Second Malignancy
| SPN . | Age at AG*/Sex . | Prior Therapy . | Preparatory Regimen . | Interval: Dx+ to Second Malignancy (mos) . | Interval: AG to Second Malignancy (mos) . | Diagnosis . |
|---|---|---|---|---|---|---|
| 55 | 45 M | MOPP × 6 | BCNU/VP/Cy | 121 | 23 | MDS |
| MOPP/ABVD × 6 | ||||||
| MOPP/BAP × 23-154 | ||||||
| Mantle radiation | ||||||
| 123 | 37 M | MOPP/ABVD × 12 | BCNU/VP/Cy | 89 | 50 | MDS |
| TLI3-167 | ||||||
| 251 | 35 M | PAVe × 83-155 | BCNU/VP/Cy | 52 | 12 | MDS |
| TLI | ||||||
| MOPP/ABV × 3 | ||||||
| 1,025 | 34 F | MOPP/ABV × 8 | CCNU/VP/Cy | 47 | 9 | Acute monoblastic leukemia |
| MOPP × 3 | ||||||
| Bronchus radiationρ | ||||||
| High dose VP3-152 | ||||||
| 483 | 48 M | PAVe × 6 | CCNU/VP/Cy | 65 | 27 | Non-small cell lung cancer |
| Mantle radiation | ||||||
| MOPP × 3 | ||||||
| 815 | 28 F | STLI3-160 | BCNU/VP/Cy | 136 | 1 | Breast cancer |
| MOPP × 6 | ||||||
| ABVD × 2 | ||||||
| DHAP × 2 |
| SPN . | Age at AG*/Sex . | Prior Therapy . | Preparatory Regimen . | Interval: Dx+ to Second Malignancy (mos) . | Interval: AG to Second Malignancy (mos) . | Diagnosis . |
|---|---|---|---|---|---|---|
| 55 | 45 M | MOPP × 6 | BCNU/VP/Cy | 121 | 23 | MDS |
| MOPP/ABVD × 6 | ||||||
| MOPP/BAP × 23-154 | ||||||
| Mantle radiation | ||||||
| 123 | 37 M | MOPP/ABVD × 12 | BCNU/VP/Cy | 89 | 50 | MDS |
| TLI3-167 | ||||||
| 251 | 35 M | PAVe × 83-155 | BCNU/VP/Cy | 52 | 12 | MDS |
| TLI | ||||||
| MOPP/ABV × 3 | ||||||
| 1,025 | 34 F | MOPP/ABV × 8 | CCNU/VP/Cy | 47 | 9 | Acute monoblastic leukemia |
| MOPP × 3 | ||||||
| Bronchus radiationρ | ||||||
| High dose VP3-152 | ||||||
| 483 | 48 M | PAVe × 6 | CCNU/VP/Cy | 65 | 27 | Non-small cell lung cancer |
| Mantle radiation | ||||||
| MOPP × 3 | ||||||
| 815 | 28 F | STLI3-160 | BCNU/VP/Cy | 136 | 1 | Breast cancer |
| MOPP × 6 | ||||||
| ABVD × 2 | ||||||
| DHAP × 2 |